Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE)

Grant R. Williams a,b,⁎, Kelly M. Kenzik a,b, Mariel Parman a, Mustafa Al-Obaidi a, Liton Francisco a, Gabrielle B. Rocque b, Andrew McDonald b, Ravi Paluri b, Rudolph M. Navari b, Lakshmin Nandagopal b, Olumide Gbolahan b, Crystal Young-Smith b, Matthew Robertson b, Smita Bhatia a

a Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, United Kingdom
b Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, United Kingdom

⁎ Corresponding author at: Divisions of Hematology/Oncology & Gerontology, Geriatrics, and Palliative Care, Institute of Cancer Outcomes and Survivorship, O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham AL 35233, United Kingdom.
E-mail address: gwilliia@uab.edu (G.R. Williams).

ARTICLE INFO

Article history:
Received 26 February 2019
Received in revised form 8 April 2019
Accepted 9 April 2019
Available online xxxx

Keywords:
Geriatric assessment
Cancer
Geriatric oncology
Aged
Gastrointestinal malignancy

ABSTRACT

Background: Integrating Geriatric Assessment (GA) in the management of older adults with cancer is recommended, yet rarely practiced in routine oncologic care. Our objective was to assess the feasibility of integrating routine GA in the management of older adults with gastrointestinal (GI) malignancies and characterize impairments in this population.

Methods: Patients ≥60yo referred for consultation to the GI Oncology clinic were asked to complete the Cancer and Aging Resilience Evaluation (CARE) on their first visit. CARE was adapted from the Cancer and Aging Research Group GA with modifications to create a completely patient-reported version of the GA. Feasibility was defined as completion of CARE by ≥80% of eligible patients during the initial consultation.

Results: Of the eligible 354 new patients seen in the GI Oncology Clinic, 323 (91.2%) completed the CARE survey. Most patients (83.1%) felt the length of time to complete was appropriate (median time of 10 min [IQR 10–15.7 min]). GA impairments were prevalent: 54.7% reported dependence in Instrumental Activities of Daily Living, 15.5% reported dependence in Activities of Daily Living, 20.9% reported polypharmacy (≥4 medications), and 36.4% had ≥2 comorbidities.

Conclusions: Performing a GA in the routine care of older adults with GI malignancies is feasible, and GA impairments are common among this population. A fully patient-reported GA such as the CARE may facilitate broader incorporation of GA in the routine clinic workflow.

© 2019 Elsevier Ltd. All rights reserved.

1. Introduction

Cancer is predominantly a disease of older adults, and the aging process results in a wide variability in health status among older adults presenting with a new diagnosis, thus complicating clinical management. Chronic age and performance status alone are insufficient to characterize the heterogeneous aging process [1]. Geriatric Assessment (GA) is a multidimensional tool developed to assess the medical, functional, and psychosocial abilities of older adults [2]. A traditional GA performed by a geriatrician can take several hours to perform, and it was recognized early on in the growing field of geriatric oncology that a comprehensive yet brief measure needed to be developed. Dr. Arti Hurria led the seminal early development and validation of a GA tool designed for use in older adults with cancer [3,4]. This brief GA was later adopted across several research studies and highlighted the large number of GA impairments that are often missed by routine clinical examination [1,5,6]. Incorporation of a GA is recommended in the management of older adults over the age of 65 or in younger patients with age-related concerns [7,8]. However, despite the growing evidence regarding the value of GA in cancer care, few oncology centers utilize GA due to perceived logistical concerns and lack of resources.

Although several previous reports have described the feasibility of performing a GA in a variety of settings, these studies have been conducted in the context of a research study with research staff facilitating the collection of information related to GA [4–6]. To improve the widespread use of GA in routine practice, it is vital to develop new care models that integrate GA into routine oncologist care without additional resource allocation. The overarching goal of our study was to evaluate the implementation of incorporating a GA in the routine care of older adults with gastrointestinal (GI) malignancies referred for initial consultation: The Cancer and Aging Resilience Evaluation (CARE).
consultation. We sought to determine the proportion of eligible patients who were able to complete the GA at their initial consultation visit. Secondary outcomes included time to completion, satisfaction with the questionnaire length, whether there was any difficulty understanding questions, whether assistance was required with the GA, and the number of missing items. Lastly, we characterized GA-identified impairments in this population.

2. Methods

All new patients over the age of 60 with a new patient visit scheduled with the GI oncology team at the University of Alabama at Birmingham (UAB) were identified as potential participants. Performing GA is recommended as part of routine evaluation and management of older adults with cancer [2,8,9]. Therefore, assessments were performed as part of routine clinical care. At check-in for their appointments, front desk staff provided a copy of the paper questionnaire on a clip board. During nurse triage the survey was collected and submitted to the clinical team prior to the clinical encounter. Clinical team reviewed and utilized as deemed appropriate for clinical care. After consultation with oncology providers, patients were approached for consent to have their data stored in our registry for future research. For any patients not wishing to consent, GA information was used only for clinical purposes. This study was approved by the institutional review board of UAB in September 2017 and recruitment began soon thereafter. Enrollment was performed on a rolling basis, starting with one provider and expanding to include GI oncology providers over the first 3 months.

The assessment employed in this study was a modified version of the Cancer and Aging Research Group (CARG) GA originally developed by Arti Hurria [4]. Modifications from the prior CARG version were made in order to streamline the assessment, tailor to a GI cancer population, and create an entirely patient-reported assessment that could be completed without the involvement of additional staff. The assessment included an evaluation of all essential domains of the GA including functional status, physical function, nutrition, health-related quality of life (HRQOL), social support, social activities, psychological status, cognitive function, comorbidities and polypharmacy [7]. The objective cognitive assessment was replaced with the Patient-Reported Outcomes Measurement Information System (PROMIS®) cognitive function short-form 4 to reduce staff burden and promote ease of use [10]. In addition, due to prior issues and uncertainty around the scoring of the mental health index (MHI) assessment of anxiety and depression, we used the PROMIS® anxiety and depression short forms. The social support questionnaire from the Medical Outcome Study was shortened to 8 items based on updated psychometric evaluations of the tool [11]. As cancer cachexia and nutrition is of particular importance in GI malignancies, we added the Patient-Generated Subjective Global Assessment (PG-SGA) of nutrition that includes 4 patient-generated components of weight history, food intake, symptoms, and activities/function [12,13]. Lastly, given the importance of HRQOL in older adults, we incorporated the PROMIS global health 10. The resultant assessment was termed the Cancer and Aging Resilience Evaluation (CARE) and consisted of 82 items across 6 pages (see supplemental materials).

The questionnaire was offered to all new patients seen for the first time in the outpatient GI oncology clinics at UAB and completion of the assessment was tracked. Reasons for non-completion were recorded. In order to demonstrate successful implementation of the assessment, our initial goal was to have ≥80% of all new patients seen for consultation to complete GA at their initial visit. Secondarily, we evaluated the self-reported time to completion, the participants’ satisfaction with length and understandability, whether assistance was required with the questionnaire, and the completeness of data by item and domains. Descriptive statistics were used to characterize the sample, and GA impairments were identified per literature-based cut-points [1,6]. Wilcoxon non-parametric tests and Pearson Chi-Square were used to compare distributions of time required to complete the CARE survey and proportions requiring assistance between those <75 and ≥75 years of age.

3. Results

From September 2017 through April 2019, 354 new patients over the age of 60 were seen in the UAB GI Oncology Clinic, of which 323 (91.2%) completed the CARE survey during their initial consultation and consented to be included in our registry. Of those that did not complete the survey, 17 were missed by the clinical team and 14 patients refused the assessment. Most common reasons for refusal were not interested in research (9 patients, 61.5%) or feeling overwhelmed (2 patients, 15.4%), and some gave no specific reason (3 patients, 21.3%). The most frequent reason the clinical team missed the survey was due to patients’ severity of illness and requiring hospitalization or hospice. Median time to completion was 10 min (Interquartile Range 10–15.7 min) (Table 1). Most patients (83.1%) felt the length of time to complete was appropriate and 93.1% reported there were no difficult questions to understand. About a quarter of patients (27.2%) required assistance from a caregiver in completing the survey. All items and domains had <10% missing data. Patients ≥75 years required more assistance (22.8 vs. 40.7%, p ≤ .01) and took longer (median of 10 vs 15 min, p = .04) to complete the CARE survey.

The mean age was 70y (range 60–96) and the most common tumor types included colon (23.2%), pancreatic (22.9%), and rectal (10.5%) cancer with predominately advanced stage diseases (stage III/IV, 70.7%) (Table 1). GA impairments were highly prevalent with 54.7% dependent in Instrumental Activities of Daily Living (IADL), 15.5% dependent in Activities of Daily Living. Furthermore, 20.9% reported ≥1 fall, 35.5% reported a performance status ≥2, 55.7% were limited in walking.

Please cite this article as: G.R. Williams, K.M. Kenzik, M. Parman, et al., Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Res, J Geriatr Oncol, https://doi.org/10.1016/j.jgo.2019.04.008
one block, 74.0% reported polypharmacy (≥4 medications), 36.4% had ≥3 comorbid conditions, 9.4% with moderate/severe cognitive impairment, 38.7% reported weight loss in past 2 weeks, and 49.0% reported limitations in social activities (Fig. 1).

4. Discussion

Over 90% of new patients seen for routine initial oncologic consultation completed the CARE GA during their first clinic visit without the assistance of research staff or additional resources. This study demonstrates the ease with which a GA can be integrated into routine oncology practice without significant resource allocation or burden to staff. The modified and completely patient-reported version of the GA maintained evaluation of all the core domains of the GA while shortening the time required and minimizing burden on staff. The time to complete the questionnaire was shorter in comparison to the CARG GA (10 min versus 27 min) with similar overall length satisfaction [4]. As the GA is recommended for routine use in older adults with cancer, the fully patient-reported and streamlined CARE may improve the implementation of a GA in the routine cancer management.

On November 7th, 2018, Arti Hurria died tragically and the world lost an irreplaceable leader in the field of geriatric oncology, and great friend and mentor to all of us in cancer and aging research. Few researchers have been as instrumental and impactful in developing and moving a field of research forward as Dr. Hurria, and her passion for improving the care of older adults with cancer was infectious. Through her development of CARG, she fostered the creation of a vast international network of multidisciplinary researchers with the single minded determination of improving the care of the growing number of older adults with cancer. Dr. Hurria not only made considerable strides by creating the brief GA tool as highlighted in the introduction, she later went on to develop and validate a chemotherapy toxicity calculator using this tool, which can be used to facilitate treatment discussions when weighting the risks and benefits of systemic chemotherapy [14,15].

Arti Hurria’s impact on the developing field of geriatric oncology is immeasurable, and she trail-blazed a path of career success as a researcher focused at the cross-section of cancer and aging that many of us strive to emulate. With our work we hope to honor Dr. Hurria’s legacy of developing the brief GA, and demonstrate a model that may help expand the number of older adults able to have a GA performed as part of their routine oncologic management in clinics across the globe.

Performing a GA not only helps assess the presence of age-related conditions and overall fitness, it has been specifically shown to predict chemotherapy toxicity and survival in older adults with cancer [2,16]. This prognostic information can help inform the risk/benefit balance of many treatment decisions particularly in complex older patients, and potentially guide treatment management [8,17]. As such, GA results have been demonstrated to strongly influence oncologists’ treatment decisions [18]. Lastly, the GA can identify many areas of impairment, such as dependency in IADL and falls, that have known effective interventions shown to be beneficial in general older adult population; how these targeted interventions impact cancer outcomes remain less understood [19,20].

The length of time required to complete the CARE survey is notably shorter than prior reports using the CARG GA (10 vs. 23–27 min) [4,6]. Besides for the complete elimination of the objective measures (specifically the Timed Up and Go and Blessed Orientation Memory and Concentration), which previously took about 6 min, the likely single biggest reason for the time reduction was not having patients write out all their medication list. The CARE survey only includes the number of medications taken on a daily basis and does not entail the participant writing out all their medications. This change was made as a medication review is already obtained as a routine part of clinical practice in most institutions/practices, and an updated list of medications is routinely available within the electronic medical record. We felt having participants repeat this medication review only lengthened the survey with little to no additional benefit.

Our study is not without some limitations. Although we were able to track all new patients within our clinic and evaluate whether they completed the GA, we did not assess how implementing the GA altered oncologic management. However, prior work has already demonstrated how GA-related information strongly influences oncologists’ treatment decisions, and our subsequent plans of the CARE registry is to explore how the GA impacts clinical management and develop improved versions.
methods for sharing this information with providers [18]. While we acknowledge the importance of objective physical and cognitive measures traditionally included in the GA and recognize the potential drawbacks of relying entirely on patient-reported information, we chose to omit the objective measures as part of our base assessment and instead have elected to incorporate these as optional assessments for specific patients were this may be of particular importance. This decision has most impacted the domain of cognition, as the use of self-reported cognitive dysfunction is relatively new within oncology [21]. Some early results suggest patient-reported cognitive dysfunction may underreport cognitive impairment while others have shown modest-high correlation with objectively assessed cognition, both of which were associated with a higher likelihood of not returning to work [22,23]. We also plan to examine the concordance of objective measures with patient-reported measures to see how many additional patients this may identify with impairment and further examine associations of patient-reported cognitive dysfunction with adverse outcomes. We purposefully used a low age (60 years) for enrollment into our registry as we felt many components of the GA are relevant to younger older patients (nutrition, anxiety, depression, etc.) and in order to allow for more meaningful age-related sub-analyses in the future. Finally, our study sample consists of patients with GI malignancies from a single center in southeast US and may not be representative of all older adult with cancer.

5. Conclusions

In summary, we have demonstrated that a patient-reported GA can be implemented as part of routine oncologic care in the management of older adults with GI malignancies and identifies a high prevalence of GA impairments in this population. As eloquently stated by Hamaker and colleagues, it’s “time to stop saying geriatric assessment is too time consuming.” [24] In the era of precision medicine, it is critical for clinicians to develop personalized treatment plans that go beyond tumor-specific markers to also include comprehensive assessments of the patient such as the GA provides [25]. Further research is currently underway to determine how best GA results can be incorporated to guide management and improve clinical decision-making for older adults in oncology.

Conflict of Interest

The authors have no conflict to disclose.

Author Contributions


Funding

Supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and the National Cancer Institute of the National Institutes of Health (K08CA234225). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jgo.2019.04.008.

References